Newer and upcoming therapies for melasma.
Indian J Dermatol Venereol Leprol
; 78(4): 417-28, 2012.
Article
em En
| MEDLINE
| ID: mdl-22772611
ABSTRACT
Melasma is one of the most common and distressing pigmentary disorders presenting to dermatology clinics. The precise cause of melasma remains unknown; however, there are many possible contributing factors. It is notably difficult to treat and has a tendency to relapse. The existing and most tried topical therapy is hydroquinone and the triple combination with tretinoin and corticosteroids, which is considered the gold standard for melasma. Besides that, azelaic acid, kojic acid, arbutin, ascorbic acid, glycolic acid and salicylic peels have also been tried with limited success. However, multiple novel topical agents are being investigated for their potential as hypopigmenting agents with unique mode of action. But, further trials are required to study their efficacy and safety before they can be further recommended. The article highlights these newer formulations and also briefly mentions about the newer chemical peels and the much hyped lasers in treating this difficult and frustrating condition.
Texto completo:
1
Tema:
Geral
/
Tratamento_medicamentoso
Bases de dados:
MEDLINE
Assunto principal:
Fármacos Dermatológicos
/
Melanose
Idioma:
En
Revista:
Indian J Dermatol Venereol Leprol
Ano de publicação:
2012
Tipo de documento:
Article